Operating cash flow of $52M in Q2 2026 exceeded net income of $47M, reflecting an OCF/NI ratio of 1.11, while buybacks of $45M were fully funded by cash generation.
Genworth Financial, Inc. (GNW) cash flow statement — 24-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 |
|---|
| Cash from Operations | 430M | 327M | 88M | 597M | 1.05B | 437M | 1.96B | 2.08B | 1.63B | 2.55B | 1.85B | 1.59B | 2.44B | 1.4B | 962M | 3.13B | 1.34B | 1.93B | 5.44B | 4.79B | 4.37B | 3.48B | 5.5B | 3.72B | 4.88B |
| Operating CF Growth % | 1529.09% | 271.59% | -85.26% | -43.09% | 140.05% | -77.7% | -5.72% | 27.31% | -36.06% | 37.91% | 16.4% | -34.74% | 74.27% | 45.43% | -69.22% | 133.91% | -30.81% | -64.52% | 13.61% | 9.76% | 25.47% | -36.72% | 47.95% | -23.9% | - |
| Operating CF / Revenue % | 6.15% | 5.14% | 1.23% | 8.1% | 14.18% | 5.75% | 23.87% | 26.98% | 20.7% | 33.99% | 22.15% | 18.61% | 27.93% | 16.22% | 9.98% | 31.49% | 13.24% | 21.29% | 54.71% | 43.07% | 42.44% | 35.55% | 53.03% | 33.79% | 43.49% |
| Net Income | 212M | 350M | 4M | 76M | 1.05B | 864M | 761M | 519M | 297M | 936M | -38M | -6M | -1.05B | 726M | 523M | 261M | 285M | -399M | -572M | 1.15B | 62M | 105M | 1.15B | -863M | -526M |
| Depreciation & Amortization | 85M | 93M | 130M | 40M | 0 | 0 | -570M | 557M | 269M | 288M | 360M | 546M | 1.08B | 61M | 639M | 743M | 756M | 782M | 884M | 802M | 745M | 853M | 1.24B | 1.35B | 1.22B |
| Stock-Based Compensation | 68M | 58M | 51M | 49M | 37M | 40M | 39M | 27M | 37M | 42M | 32M | 16M | 30M | 41M | 26M | 31M | 44M | 26M | 23M | 41M | 49M | 0 | 0 | 0 | 0 |
| Deferred Taxes | -31M | -55M | -103M | 48M | 315M | 275M | 268M | 139M | 5M | -368M | 145M | -196M | -487M | -79M | 88M | -309M | -294M | -476M | -430M | 252M | 368M | 891M | -1.2B | -63M | -55M |
| Other Non-Cash Items | -971M | -925M | -618M | -933M | -884M | -1.76B | -646M | -699M | -883M | -363M | -321M | -788M | -777M | -812M | -1.17B | 14M | -1.36B | -87M | 1.75B | -1.66B | -418M | -329M | -1.36B | -177M | -376M |
| Working Capital Changes | 953M | 806M | 624M | 1.32B | 535M | 1.01B | 2.11B | 1.54B | 1.91B | 2.02B | 1.67B | 2.02B | 3.64B | 1.46B | 854M | 2.38B | 1.9B | 2.08B | 3.79B | 4.2B | 3.56B | 1.96B | 5.67B | 3.47B | 4.62B |
| Cash from Investing | 181M | 518M | 861M | 1.26B | 733M | 896M | -1.15B | 1.3B | -622M | -759M | -2.12B | -404M | -1.84B | -580M | -722M | -59M | -1.81B | 820M | 1.97B | -1.88B | -2.9B | -3.28B | -5.4B | -681M | -6.53B |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 267M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 463M | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | -98M | -334M | -274M | -384M | -460M | -242M | -267M | 1.4B | 0 | -5M | 39M | 273M | 0 | 365M | 46M | 207M | -37M | -51M | -22M | -31M | -511M | 0 | 1M | 1.59B | -61M |
| Purchase of Investments | -2.68B | -4.33B | -4.45B | -3.23B | -4.04B | -5.22B | -9.84B | -7.29B | -10.71B | -9.59B | -11.68B | -9.75B | -9.53B | -10.8B | -12.33B | -12.41B | -13.24B | -10.18B | -6.98B | -16.89B | -16.78B | -13.25B | -16.86B | -29.5B | -35.41B |
| Sale/Maturity of Investments | 1.3B | 5.02B | 5.19B | 4.66B | 5.39B | 6.45B | 8.29B | 7.32B | 10.35B | 8.99B | 9.52B | 9.11B | 7.85B | 9.56B | 11.33B | 11.52B | 10.81B | 10.62B | 9.73B | 15.16B | 7.34B | 7.05B | 16.67B | 26.65B | 28.88B |
| Other Investing | 1.65B | 160M | 392M | 215M | -158M | -99M | 387M | -128M | -266M | -157M | 6M | -34M | -158M | 295M | 237M | 629M | 648M | 431M | -1.23B | -112M | 7.05B | 2.92B | -5.21B | 583M | 62M |
| Cash from Financing | -422M | -857M | -1.11B | -1.44B | -1.55B | -2.42B | -1.51B | -2.22B | -1.62B | -1.77B | -2.93B | -42M | 205M | -149M | -1.1B | -1.64B | -1.51B | -5.31B | -2.91B | -2.29B | -835M | -248M | -791M | -2.71B | 2.29B |
| Dividends Paid | 0 | 0 | -21M | 0 | 0 | 0 | 0 | -87M | -97M | -107M | -138M | 0 | 0 | -535M | -50M | -67M | -43M | -10M | -175M | -163M | -145M | -128M | -1.61B | -3.23B | 0 |
| Share Repurchases | -324M | -319M | -189M | -296M | -64M | 0 | 0 | -22M | 0 | -33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -76M | -1.12B | -1B | -500M | 0 | 0 | 0 |
| Stock Issued | 0 | 0 | 0 | 0 | 0 | 529M | 0 | 22M | 0 | 0 | 0 | 226M | 517M | 0 | 0 | 0 | 0 | 622M | 0 | 600M | 0 | 0 | 1.91B | 261M | 0 |
| Debt Issuance (Net) | -3M | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | 1000K | -1000K | -1000K | 1000K | -1000K | 1000K | -1000K | 1000K | 1000K | -1000K | 1000K | -1000K |
| Other Financing | -76M | -531M | -831M | -1.11B | -1.19B | -1.41B | -1.44B | -1.68B | -1.42B | -1.73B | -927M | 25M | 239M | -389M | -12M | -1.13B | -2.47B | 770M | -3.91B | -1.41B | -335M | -61M | 753M | -132M | 2.37B |
| Net Change in Cash | 189M | -12M | -167M | 416M | 228M | -1.08B | -685M | 1.16B | -698M | 91M | -3.21B | 1.05B | 704M | 561M | -835M | 1.36B | -1.87B | -2.33B | 4.24B | 622M | 594M | -88M | -590M | 413M | 688M |
| Exchange Rate Effect | 0 | 0 | -1M | 1M | 0 | 1M | 15M | 1M | -88M | 64M | -10M | -70M | -103M | -109M | 26M | -69M | 121M | 232M | -258M | 6M | -38M | -42M | 107M | 92M | 37M |
| Cash at Beginning | 2.12B | 2.05B | 2.21B | 1.8B | 1.57B | 2.66B | 3.34B | 2.18B | 2.88B | 2.78B | 5.99B | 4.92B | 4.21B | 3.65B | 4.49B | 3.13B | 5B | 7.33B | 3.09B | 2.47B | 1.88B | 1.96B | 1.98B | 1.57B | 881M |
| Cash at End | 1.99B | 2.04B | 2.05B | 2.21B | 1.8B | 1.57B | 2.66B | 3.34B | 2.18B | 2.88B | 2.78B | 5.96B | 4.92B | 4.21B | 3.65B | 4.49B | 3.13B | 5B | 7.33B | 3.09B | 2.47B | 1.88B | 1.39B | 1.98B | 1.57B |
| Free Cash Flow | 430M | 327M | 88M | 597M | 1.05B | 437M | 2.23B | 2.08B | 1.63B | 2.55B | 1.85B | 1.59B | 2.44B | 1.4B | 962M | 3.13B | 1.34B | 1.93B | 5.91B | 4.79B | 4.37B | 3.48B | 5.5B | 3.72B | 4.88B |
| FCF Growth % | 88.6% | 271.59% | -85.26% | -43.09% | 140.05% | -80.38% | 7.12% | 27.31% | -36.06% | 37.91% | 16.4% | -34.74% | 74.27% | 45.43% | -69.22% | 133.91% | -30.81% | -67.3% | 23.27% | 9.76% | 25.47% | -36.72% | 47.95% | -23.9% | - |
| FCF Margin % | 6.15% | 5.14% | 1.23% | 8.1% | 14.18% | 5.75% | 27.12% | 26.98% | 20.7% | 33.99% | 22.15% | 18.61% | 27.93% | 16.22% | 9.98% | 31.49% | 13.24% | 21.29% | 59.37% | 43.07% | 42.44% | 35.55% | 53.03% | 33.79% | 43.49% |
| FCF per Share | 1.11 | 0.79 | 0.2 | 1.26 | 2.05 | 0.85 | 4.35 | 4.08 | 3.26 | 5.09 | 3.72 | 3.2 | 4.91 | 2.81 | 1.95 | 6.33 | 2.71 | 4.28 | 13.63 | 10.7 | 9.3 | 7.18 | 11.21 | 7.59 | 10.05 |
Quick answers to the most common questions about buying GNW stock.
Genworth Financial, Inc. (GNW) generated $327.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Genworth Financial, Inc. (GNW) generated $327.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Genworth Financial, Inc. (GNW) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Genworth Financial, Inc. (GNW) spent $319.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Legacy LTC reserve volatility
Metrics are mathematically derived from official filings.
Underwriting Cash Generation Stabilizes
Genworth's operating cash flow averaged $75.8 million per quarter over the last five quarters, with Q2 2026 at $52 million, indicating stable underwriting cash generation despite revenue contraction, as per recent SEC filings.
The operating cash flow to net income ratio has been volatile, ranging from 0.12 to 100, but the recent quarters show a more consistent pattern, with Q2 2026 at 1.11. This suggests that cash generation is aligning with reported earnings, though the underlying revenue decline of 10.9% YoY may pressure future cash flows. The stability in OCF appears to be supported by disciplined claims management and premium collections, but investors should monitor whether this can persist as legacy blocks run off.
Claims Payments Reflect Legacy Runoff
Claims and loss payments have declined from $1.7 billion in Q3 2025 to $1.2 billion in Q1 2026, a 29% reduction, suggesting a tapering of legacy LTC claims, as reported in the cash flow statement.
The reduction in claims payments may indicate that the company is experiencing favorable claims development, possibly due to policy lapses or improved morbidity assumptions. However, the persistence of medical cost inflation could reverse this trend, and the company's ability to secure premium rate increases will be critical. The declining claims payments, if sustained, could improve underwriting cash flow, but the absence of forward guidance limits visibility.
Portfolio Rotation Supports Liquidity
Investment purchases and sales have been substantial, with Q2 2026 showing $318 million in purchases and $2.3 billion in sales, indicating active portfolio management to fund operations and capital returns, based on reported figures.
The net sales of investments in Q2 2026 (approximately $2 billion) suggest that Genworth is liquidating a portion of its investment portfolio to support cash needs, possibly for debt reduction or share buybacks. This may indicate a strategic shift towards more liquid assets, but it also raises questions about the sustainability of investment income if the portfolio is being reduced. The company's large cash position of $2.036 billion provides a buffer, but the reliance on portfolio sales to generate cash may not be sustainable long-term.
Buybacks Funded by Cash Generation
Genworth repurchased $45 million of shares in Q2 2026, funded by operating cash flow of $52 million, indicating that buybacks are covered by cash generation, as per the latest quarterly statement.
The buyback activity, while modest, appears to be supported by operating cash flow, which is a positive sign for capital return sustainability. However, the company also sold investments to fund these repurchases, suggesting that cash generation alone may not be sufficient. The lack of dividends and the focus on buybacks may indicate management's confidence in the underlying cash flow, but the overall revenue decline warrants caution.
Earnings Quality Supported by Cash Conversion
Operating cash flow exceeded net income in Q2 2026 ($52 million vs $47 million), with a cumulative OCF/NI ratio of 1.11, indicating that reported earnings are backed by cash, as reported in financial statements.
The positive cash conversion suggests that earnings are not solely reliant on non-cash accruals, which is reassuring given the complexity of LDTI accounting. However, the volatility in OCF/NI across quarters (ranging from -0.77 to 100) indicates that earnings quality can fluctuate significantly. The Q2 2026 beat may be supported by favorable reserve developments, but the absence of forward guidance makes it difficult to assess the sustainability of this cash generation.
Cash Flow Obscures Legacy Risks
Despite stable operating cash flow, the reliance on investment sales and declining revenue may obscure underlying legacy LTC risks, as the company's cash flow statement does not fully reflect future reserve needs, based on reported data.
The cash flow statement shows significant investment portfolio turnover, which may mask the true liquidity position if the portfolio is being depleted to fund operations. Additionally, the decline in claims payments could be temporary, and the company's exposure to medical cost inflation remains a key risk. Investors should monitor whether the company can maintain cash generation without further portfolio liquidation, as this could signal underlying stress in the legacy blocks.